The recent data from the VUV 105 trial clearly indicates that...

The recent data from the VUV 105 trial clearly indicates that Scenesse (afamelanotide) is effective in promoting the repigmentation of vitiligo lesions. These findings suggest a promising avenue for addressing vitiligo, though several questions remain regarding the full scope of its efficacy and potential applications.

Confirmed Outcomes:

• Scenesse has been shown to cause the skin to darken, a response that extends to areas affected by vitiligo, leading to visible repigmentation of lesions.
• Once treatment with Scenesse is discontinued, repigmented skin appears to revert to its baseline color.

Unanswered Questions:

• Long-term Efficacy: Will extended treatment periods result in complete repigmentation for patients who have not yet achieved full color restoration? Will extending the treatment period from 5 months to 12 months result in 100% repimentation?
• Topical Use for Maintenance: Is the topical formulation to serve as a "touch-up" solution or targeted treatment for small, isolated areas of vitiligo? With the ultimate goal for a "botox" viral adoption.

While no outcomes are guaranteed, the future of Scenesse in the treatment of vitiligo looks increasingly promising. If Clinuvel Pharmaceuticals successfully receives regulatory approval for vitiligo and introduces a topical treatment for localized use, there is significant potential for widespread adoption. Such advancements could position the company to surpass a market valuation of $10 billion IMO, especially if the treatment gains traction among the wider general public.

Time to buy yourself some CUV shares.